Genelux Corporation Appoints Jason Litten, M.D., as Chief Medical Officer to Advance Olvi-Vec Development
Genelux Corporation appointed Jason Litten, M.D., as Chief Medical Officer effective January 2, 2026.
Dr. Litten will oversee all clinical development and medical strategy, focusing on advancing Olvi-Vec through pivotal milestones in ovarian and lung cancer.
Dr. Litten has over 20 years of experience in oncology drug development, including prior CMO roles at Chimeric Therapeutics and Artiva Biotherapeutics.
Thomas Zindrick, President, CEO, and Chairman, praised Dr. Litten's strategic vision and track record in leading complex clinical programs.
As part of the appointment, Dr. Litten received an inducement stock option for 275,000 shares under the 2023 Inducement Plan per Nasdaq rules.